Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Biotech
  • Healthcare
  • Cleantech
  • Technology
  • Other

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • IP Venture Fund II
  • Top 10 Holdings
    by value
Pharma & Biotech

University: Southampton

Company Stage: Private (post-seed)

Website: http://www.karustherapeutics.com

Karus Therapeutics

Karus Therapeutics is aiming to make the treatment of inflammatory diseases and cancer more effective through the development of best-in-class small-molecule drugs that target epigenetic mechanisms and lipid kinase signalling pathways.

The outstanding potency, efficacy and excellent tolerability of Karus’s HDAC inhibitors (HDI) represent a unique and innovative approach to this important drug target and brings the promise of a new gold-standard in the treatment of rheumatoid arthritis, psoriasis and cancer.

Karus’s lipid kinase signalling programme brings together a world-class research and development team that are using new insights to the design and development of innovative drugs to treat inflammatory disease and cancer.

As at 30 June 2014

IP Group holding

IP Venture Fund* holding

8.6%

5.9%
 

*IP Group has a 10%
economic interest in IP
Venture Fund

Holdings represent undiluted beneficial equity interest excluding debt

Related news

12 Oct 2006

There is currently no news available.

More portfolio news